3 Specialty Performance Chemicals Maker, Contract Drug Maker and Active Ingredients and Formulations Company Stocks With a Strong Future Roadmap: Clean Science and Technology, Innova Captab and Laurus Labs

Specialty chemical, contract drug and API stocks offer a focused view of a sector where demand keeps widening. Clean Science and Technology, Innova Captab and Laurus Labs cover a specialty performance chemicals maker, a contract drug maker and an active ingredients and formulations company.

This list covers three specialty chemical, contract drug and API stocks with complete current figures: Clean Science and Technology, Innova Captab and Laurus Labs. Every figure comes from the latest reported financials and the 30 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Specialty Chemical, Contract Drug and API Stocks?

Specialty chemical, contract drug and API stocks are listed companies that make performance chemicals and pharma intermediates, produce formulations for other drug brands, and supply active ingredients and finished medicines to global buyers. Their earnings depend on export orders, approvals and product mix.

Specialty Chemical, Contract Drug and API Stocks at a Glance

On valuation, Clean Science and Technology trades at a P/E below the industry P/E, while Innova Captab and Laurus Labs trade above it, which reflects the growth the market already expects. Readers comparing specialty chemical, contract drug and API stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in specialty chemical, contract drug and API stocks can use the coming numbers to test whether growth is holding.

Why Do Specialty Chemical, Contract Drug and API Stocks Have a Strong Roadmap in India?

Specialty chemical, contract drug and API stocks have a strong roadmap in India because niche chemistry leadership, drug makers outsourcing more production and steady global demand for medicines keep widening the market for these pharma and chemical companies.

• Niche chemistry. Leading products support pricing strength.
• Contract work. Brands outsource production to specialists.
• Global demand. Regulated markets buy Indian medicines.

Why Clean Science and Technology Features Among These Specialty Chemical, Contract Drug and API Stocks

Among the specialty chemical, contract drug and API stocks on this list, Clean Science and Technology makes specialty chemicals including performance chemicals, pharma intermediates and FMCG chemicals using its own catalytic processes.

Revenue rose from Rs 715 crore in FY22 to Rs 989 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 230 crore, a net margin of 23.2%.

In the June 2026 quarter, revenue grew 13.4% year on year to Rs 291 crore, while net profit rose 4.7% to Rs 73.3 crore. The company has a return on equity of 14.5%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 8,080 crore. The stock trades at a P/E of 34.7, below the industry P/E of 35.1.

Roadmap: The company uses cleaner, in-house developed processes that give it cost advantages in products such as MEHQ and guaiacol. It is adding new products and capacity, and carries no debt.

What to watch: Watch new product launches and capacity utilisation at its newer plants.

Why Innova Captab Features Among These Specialty Chemical, Contract Drug and API Stocks

Among the pharma and chemistry shares on this list, Innova Captab is a Himachal Pradesh-based pharmaceutical company that makes formulations for other pharma companies, manufactures its own branded generics and supplies active ingredients.

In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%.

Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0.

Roadmap: The company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.

What to watch: Watch the growth in the branded business and the utilisation of expanded capacity.

Why Laurus Labs Features Among These Specialty Chemical, Contract Drug and API Stocks

Among the three companies on this list, Laurus Labs is a Hyderabad-based pharmaceutical company with businesses in active ingredients, finished formulations, custom synthesis and biotechnology, with a leading position in anti-retroviral medicines.

The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0.

Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore.

Roadmap: The company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.

What to watch: Follow the ramp-up of new capacity in formulations and the order flow in custom synthesis.

Clean Science and Technology vs Innova Captab vs Laurus Labs on Key Financials

The table below sets the three specialty chemical, contract drug and API stocks side by side on revenue, profit and margin, using reported figures.

Laurus Labs posts the highest return on equity in this group at 16.8%. Laurus Labs has the largest FY26 revenue at Rs 6,868 crore, and Innova Captab shows the fastest revenue growth with a 19.5% compound annual rate. A useful habit with specialty chemical, contract drug and API stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Specialty Chemical, Contract Drug and API Stocks

Every theme carries risks that deserve a check before any decision. For these specialty chemical, contract drug and API stocks, the main points are: Long-term pharma and chemistry shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Currency moves. Export earnings move with the rupee.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter specialty chemical, contract drug and API stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Specialty Chemical, Contract Drug and API Stocks

Specialty chemical, contract drug and API stocks reward patient research into demand, execution and financial strength. Clean Science and Technology, Innova Captab and Laurus Labs each have a clear plan to grow. Based on the 30 October 2026 close, Clean Science and Technology trades at Rs 715.6, Innova Captab at Rs 1,025.3 and Laurus Labs at Rs 2,405.5. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these specialty chemical, contract drug and API stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track specialty chemical, contract drug and API stocks, set price alerts and get research-backed stock ideas.

What are specialty chemical, contract drug and API stocks?

Ans. Specialty chemical, contract drug and API stocks are listed companies that make performance chemicals and pharma intermediates, produce formulations for other drug brands, and supply active ingredients and finished medicines to global buyers. Their earnings depend on export orders, approvals and product mix. This list looks at three of them, Clean Science and Technology, Innova Captab and Laurus Labs, using reported FY22 to FY26 financials and the 30 October 2026 closing prices.

Which specialty chemical, contract drug and API stocks are covered in this list?

Ans. This list covers Clean Science and Technology, Innova Captab and Laurus Labs. Based on the 30 October 2026 close, Clean Science and Technology traded at Rs 715.6, Innova Captab at Rs 1,025.3 and Laurus Labs at Rs 2,405.5. Their return on equity ranges from 12.9% to 16.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 19.5%.

Why do specialty chemical, contract drug and API stocks have a strong future roadmap in India?

Ans. Specialty chemical, contract drug and API stocks have a strong roadmap in India because niche chemistry leadership, drug makers outsourcing more production and steady global demand for medicines keep widening the market for these pharma and chemical companies. The main drivers are as follows. Niche chemistry. Leading products support pricing strength. Contract work. Brands outsource production to specialists. Global demand. Regulated markets buy Indian medicines. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Clean Science and Technology performed financially?

Ans. Revenue rose from Rs 715 crore in FY22 to Rs 989 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 230 crore, a net margin of 23.2%. In the June 2026 quarter, revenue grew 13.4% year on year to Rs 291 crore, while net profit rose 4.7% to Rs 73.3 crore. The company has a return on equity of 14.5%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 8,080 crore. The stock trades at a P/E of 34.7, below the industry P/E of 35.1. Looking ahead, the company uses cleaner, in-house developed processes that give it cost advantages in products such as MEHQ and guaiacol. It is adding new products and capacity, and carries no debt.

How has Innova Captab performed financially?

Ans. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0. Looking ahead, the company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.

How has Laurus Labs performed financially?

Ans. Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0. Looking ahead, the company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.

What risks should investors check before buying specialty chemical, contract drug and API stocks?

Ans. Investors should check a few risks before buying specialty chemical, contract drug and API stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of specialty chemical, contract drug and API stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 30 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.